ILEOSTIM Trial: Assessing Efferent Loop Stimulation Before Ileostomy Reversal
Overview
The ILEOSTIM trial is a multicentre randomized controlled study evaluating whether preoperative efferent loop stimulation reduces postoperative ileus (POI) incidence after loop ileostomy reversal. The trial compares outcomes including POI rates, complications, length of hospital stay, and functional recovery between stimulated and non-stimulated groups.
Background
Loop ileostomy is commonly used after low anterior resection to prevent severe intra-abdominal sepsis from anastomotic leakage. However, reversal surgery carries a high risk of postoperative complications, especially POI, which occurs in up to 32% of cases. Structural and functional changes in the defunctionalized bowel may contribute to POI development. Preoperative stimulation of the excluded bowel segment may improve bowel function and reduce POI, but optimal stimulation methods and protocols remain unclear.
Data Highlights
The trial will randomize adult patients undergoing elective loop ileostomy reversal after rectal cancer surgery into two groups: one receiving daily efferent limb stimulation for 2 weeks preoperatively and a control group without stimulation. Primary outcome is POI incidence defined by clinical criteria from postoperative day 3 onwards. Secondary outcomes include length of hospital stay, time to oral intake, morbidity classified by Clavien–Dindo scale, and mid-term outcomes such as readmission and low anterior resection syndrome (LARS) scores at 1 and 6 months.
Key Findings
Loop ileostomy reversal is associated with a high incidence of postoperative ileus (up to 32%).
Preoperative stimulation of the efferent ileostomy limb may improve bowel absorptive and motor function by reversing microbial dysbiosis and atrophy.
The ILEOSTIM trial uses a standardized stimulation protocol involving daily irrigation with saline and nutritional thickener for 2 weeks before surgery.
Randomization is 1:1, with surgeons using either stapled or hand-sewn anastomosis techniques consistently per center.
Primary outcome is POI incidence defined by intolerance to oral intake from postoperative day 3, requiring nasogastric tube or associated symptoms.
Secondary outcomes include length of hospital stay, morbidity, and functional outcomes including LARS scores at 1 and 6 months.
Clinical Implications
If preoperative efferent loop stimulation reduces POI incidence, it could become a simple, non-invasive intervention to improve recovery after ileostomy reversal. Standardizing stimulation protocols and identifying optimal techniques may reduce postoperative complications and shorten hospital stays. This trial's results will inform best practices for managing patients undergoing ileostomy reversal after rectal cancer surgery.
Conclusion
The ILEOSTIM trial aims to provide high-quality evidence on the efficacy of preoperative efferent loop stimulation in reducing postoperative ileus and improving outcomes after loop ileostomy reversal. Its findings may guide future clinical protocols to enhance patient recovery.
